(Press-News.org) The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC). Called the Pragmatica-Lung Study (or S2302), this is one of the first NCI-supported clinical trials to use a trial design that removes many of the barriers that prevent people from joining clinical trials. This “pragmatic” approach aims to increase accessibility to clinical trials.
The study is part of a broader effort by NIH and the U.S. Food and Drug Administration (FDA) to modernize clinical trials. Pragmatic clinical trials have fewer and simpler eligibility criteria than conventional trials, while still ensuring the safety of patients. The hope is that this type of simplified trial can be less burdensome to patients and investigators, accrue study participants faster, be more representative of the real-world patient population, and serve as a model for future cancer clinical trials.
“This study is designed to eliminate potential barriers to enrollment and provides a model for increasing diversity and enrollment in clinical trials,” said Monica M. Bertagnolli, M.D., director of NCI. “Pragmatica-Lung, with its critical public and private partnerships, reflects the innovative approaches NCI is taking to achieve the Cancer Moonshot℠ goals, including reducing the cancer death rate by 50% within the next 25 years.”
The trial will evaluate whether a combination of two FDA-approved medications, ramucirumab (Cyramza, manufactured by Eli Lilly and Company) and pembrolizumab (Keytruda, manufactured by Merck), improves overall survival (how long people live) over standard treatment in people with advanced NSCLC whose disease has progressed after previous treatment with immunotherapy and chemotherapy.
“These trials will make it easier for physicians who do not work in big academic medical centers to enroll their patients, resulting in participation by more diverse populations,” said James H. Doroshow, M.D., director of NCI’s Division of Cancer Treatment and Diagnosis. “Making trials more accessible, while upholding rigorous scientific and safety standards, means that more health care practitioners and patients will have an opportunity to participate.”
The trial will enroll up to 700 participants from around the United States. Adults ages 18 and older with stage 4 or recurrent NSCLC who were previously treated with immune checkpoint inhibitors (a type of immunotherapy) and chemotherapy will be randomly assigned to receive either ramucirumab plus pembrolizumab or standard treatment. The study will look primarily at how long patients in the two groups live and is expected to complete enrollment by the end of 2025.
Pragmatica-Lung seeks to confirm the encouraging results of a randomized phase 2 clinical trial (S1800A) conducted as part of the Lung Cancer Master Protocol (Lung-MAP), the first lung cancer precision medicine trial supported by NCI. That trial involved 136 patients with advanced NSCLC who had been previously treated with chemotherapy and immunotherapy, and it found evidence that the combination of ramucirumab plus pembrolizumab extended survival compared with standard treatment. Ramucirumab is a targeted drug that works by preventing new blood vessels from growing, and pembrolizumab is an immunotherapy that helps the body’s immune system attack the cancer.
The pragmatic approach is most appropriate for trials in which the drugs being studied have already been approved and their side effects are well understood, Dr. Doroshow said.
NCI collaborators for the Pragmatica-Lung Study include the SWOG Cancer Research Network, which designed and is leading the trial in collaboration with the Alliance for Clinical Trials in Oncology. The study will be conducted with the participation of SWOG, Alliance, and two other U.S. NCI National Clinical Trials Network (NCTN) groups that focus on cancer in adults, ECOG-ACRIN Cancer Research Group and NRG Oncology. Together, these four NCTN groups represent more than 1,600 cancer treatment institutions in the United States, and doctors from any of these sites can enroll patients on the trial.
MEDIA BRIEFING
WHAT: Learn more about the Pragmatica-Lung Study and ask questions of the NCI leaders and study investigators. The information from the media briefing is embargoed until Wednesday, April 12, 2023, at 11:00 a.m. ET. By registering and attending, you are agreeing to honor the embargo.
WHO:
James H. Doroshow, M.D., director of NCI’s Division of Cancer Treatment and Diagnosis
Meg Mooney, M.D., associate director of NCI’s Cancer Therapy Evaluation Program in the Division of Cancer Treatment and Diagnosis
Jhanelle E. Gray, M.D., chair of the SWOG Lung Committee and chair of the Department of Thoracic Oncology at Moffitt Cancer Center
Karen L. Reckamp, M.D., study chair for Pragmatica-Lung and director of medical oncology at Cedars-Sinai Cancer
Judy Johnson, M.B.A., lung cancer research advocate
WHEN: Tuesday, April 11, 2023, at 12:00 p.m. ET
WHERE: Register by emailing: ncipressofficers@nih.gov
###
About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at www.cancer.gov or call NCI’s contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237).
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov.
END
Acylceramides and protein-bound ceramides are vital for the formation of the oral barrier in mice, similar to their role in skin, protecting from infection.
The skin is the body’s first line of defense against the environment, particularly against pathogens, chemicals, and allergens. It is now known that a class of biological molecules called acylceramides and their metabolites, protein-bound ceramides, are essential to the formation of this barrier. The outermost tissues of the mouth are closely related to the skin and have similar functions—an oral barrier. However, little ...
Washington, DC—Our planet’s water could have originated from interactions between the hydrogen-rich atmospheres and magma oceans of the planetary embryos that comprised Earth’s formative years, according to new work from Carnegie Science’s Anat Shahar and UCLA’s Edward Young and Hilke Schlichting. Their findings, which could explain the origins of Earth’s signature features, are published in Nature.
For decades, what researchers knew about planet formation was based ...
About The Study: In this randomized clinical trial, postoperative follow-up for patients undergoing breast reconstruction and gynecologic oncology surgery using smartphone app–assisted monitoring led to improved quality of recovery and equal satisfaction with care compared with conventional in-person follow-up.
Authors: Claire Temple-Oberle, M.D., M.Sc., of the University of Calgary in Calgary, Alberta, Canada, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamasurg.2023.0616)
Editor’s ...
Substance use disorder affects 20 million Americans, and more than 100,000 people died from a drug overdose in 2021, according to the Centers for Disease Control and Prevention. While the medication methadone has the strongest evidence-based effectiveness to prevent relapse, about half of patients drop out of their treatment within one year of initiation. The solution could lie in taking a simple “sugar pill” or placebo along with the methadone, according to a randomized clinical trial led by researchers at the University of Maryland School of Medicine.
In a randomized ...
Liver cancer is the third leading cause of cancer death and the sixth most common cancer type worldwide. Major risk factors include environmental and metabolic stressors, such as obesity, viral hepatitis and steatohepatitis (fatty and inflamed liver).
These stressors damage the liver by killing hepatocytes, the major cell type in the liver. The cell death then triggers an inflammatory response which signals the liver to generate a new batch of hepatocytes. But this sudden push towards cellular proliferation also increases the risk of tumor formation.
In ...
A clinical trial that breaks new ground with its dramatically streamlined design and unusually broad eligibility criteria is now opening and available to patients with stage 4 or recurrent non-small cell lung cancer at cancer treatment clinics all across the United States.
The S2302 Pragmatica-Lung trial, developed and led by the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), is designed to be easier for institutions to open and run and with few limits on eligibility, making it available to a larger group of patients with advanced non-small cell lung ...
Yin-Yang theory is an ancient Chinese philosophy in which Yin-Yang forces are interdependent and work in opposition to each other to create balance.
Recently, inspired by this ancient theory, a research team led by Prof. GUO Xin and Prof. LI Can from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS) has revealed the origin of the stability of Dion–Jacobson (DJ) phase two-dimensional (2D) perovskite materials.
Their findings were published in Joule on April 12.
DJ 2D perovskites, a class of organic–inorganic ...
CAMBRIDGE, MA -- Human skin is home to millions of microbes. One of these microbes, Staphylococcus aureus, is an opportunistic pathogen that can invade patches of skin affected by eczema, also known as atopic dermatitis.
In a new study, researchers at MIT and other institutions have discovered that this microbe can rapidly evolve within a single person’s microbiome. They found that in people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin.
This study marks ...
PLYMOUTH MEETING, PA [April 12, 2023] — The NCCN 2023 Annual Conference took place in-person in Orlando and virtually, with a particular focus on human connection. That connection was underscored with more than 2,000 registrants from across the continuum of cancer care, including approximately 1,000 who returned in-person for the first time since 2019. Educational sessions highlighted the importance of ensuring care meets the latest standards while also rejecting a one-size-fits-all approach.
“At NCCN, we don’t shy away from difficult discussions; we want our conference attendees to take away the message that ...
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer using a structure-based generative chemistry approach enabled by the Chemistry42 multi-modal generative reinforcement learning platform. The research was published in the American Chemical Society’s Journal of Medicinal Chemistry, a leading journal in medicinal chemistry.
As members of the CDK family, CDK8 and its paralog protein CDK19 play critical roles in regulating transcription of ...
